Oct 3, 2024 · Acquired thrombotic thrombocytopenic purpura (aTTP) affects the way your blood clots and helps cause bleeding. Learn what causes aTTP and how to spot the symptoms.

Thrombotic thrombocytopenic purpura (TTP), acquired is a blood disorder characterized by low platelets (i.e., thrombocytopenia), small areas of bleeding under the skin (i.e., purpura), low red blood cell count, and hemolytic anemia. TTP causes blood clots (thrombi) to form in small blood vessels throughout the body.

Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life‐threatening autoimmune thrombotic microangiopathy. Current standard of care is therapeutic plasma exchange, immunosuppression, and caplacizumab, an anti‐von Willebrand factor nanobody, which is effective in treating aTTP episodes.

To investigate the efficacy and safety of rituximab (RTX) as first-line treatment of acquired thrombotic thrombocytopenic purpura (aTTP).

Acquired thrombotic thrombocytopenic (aTTP) purpura is a life-threatening condition that can lead to devastating thromboembolic events. Recently, caplacizumab has been shown to rapidly restore platelet numbers and reduce the risk of severe end-organ ...

Jan 9, 2019 · In acquired thrombotic thrombocytopenic purpura (TTP), an immune-mediated deficiency of the von Willebrand factor–cleaving protease ADAMTS13 allows unrestrained adhesion of von...

Acquired thrombotic thrombocytopenia purpura (aTTP) is caused by autoantibody-mediated severe deficiency of the von Willebrand factor (vWF) cleaving protease ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13), with subsequent accumulation of ultra-large vWF-mu …

We report three patients with a first acute episode of aTTP who were successfully treated with a paradigm-changing scheme including standard of care (caplacizumab, steroids and PE) plus upfront therapy with rituximab and intravenous immunoglobulins (CASPERI).

Acute/relapsed acquired thrombotic thrombocytopenic purpura (aTTP) may be associated with BNT162b2 vaccine. Patients with aTTP should be evaluated for A Disintegrin and Metalloproteinase with a ThromboSpondin type 1 motif, member 13 (ADAMTS‐13) activity before and after vaccination.

Acute/relapsed acquired thrombotic thrombocytopenic purpura (aTTP) may be associated with BNT162b2 vaccine. Patients with aTTP should be evaluated for A Disintegrin and Metalloproteinase with a ThromboSpondin type 1 motif, member 13 (ADAMTS‐13) activity before and after vaccination.